Review




Structured Review

CapitalBio Corporation maldi-tof mass spectrophotometry
Maldi Tof Mass Spectrophotometry, supplied by CapitalBio Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/maldi+tof+ms/pmc09275392-90-11-4
Average 90 stars, based on 1 article reviews
maldi-tof mass spectrophotometry - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

Mass Spectrometry:

Article Title: A Variant in COX-2 Gene Is Associated with Left Main Coronary Artery Disease and Clinical Outcomes of Coronary Artery Bypass Grafting
Article Snippet: Genotyping of the single nucleotide polymorphisms (SNPs, COX-2 rs5275, rs5277, and rs689466) was performed by MALDI-TOF MS support from CapitalBio Corporation (Beijing, China) [ – ].

Article Title: A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
Article Snippet: SNPs were genotyped in Capitalbio Technology Corporation (Beijing, China) by using MALDI-TOF mass spectrophotometry to detect allele-specific primer extension products with the MassARRAY platform (Sequenom, Inc.).

Article Title: Comparative Analysis of Salinity-Induced Proteomic Changes in Cotton (Gossypium hirsutum L.)
Article Snippet: MALDI-TOF-MS ananlysis can deliver high resolution and accurate mass determination of biomolecules including protein digests, which is completed by biotech company (CapitalBio Corporation in China).

Article Title: Absence of association between major vault protein (MVP) gene polymorphisms and drug resistance in Chinese Han patients with partial epilepsy.
Article Snippet: Journal of the Neurological Sciences xxx (2015) xxx–xxx JNS-14106; No of Pages 5 Contents lists available at ScienceDirect Journal of the Neurological Sciences j ourna l homepage: www.e lsev ie r .com/ locate / jns Absence of association between major vault protein (MVP) gene polymorphisms and drug resistance in Chinese Han patients with partial epilepsy Luo Zhou a, Mengqi Zhang a, Hongyu Long a, Lili Long a, Yuanyuan Xie a, Zhaoqian Liu b, Jin Kang a, Qihua Chen a, Li Feng a,⁎, Bo Xiao a,⁎ a Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R.. China b Institute of Clinical Pharmacology, Central South University, Changsha, Hunan 410008, P.R.. China ⁎ Corresponding authors.

Article Title: Interleukin-6 Receptor rs7529229 T/C Polymorphism Is Associated with Left Main Coronary Artery Disease Phenotype in a Chinese Population
Article Snippet: IL-1A rs1800587 C/T, IL-1B rs16944 G/A, IL-6 rs1800796 C/G, IL-10 rs1800872 A/C and IL-10 rs1800896 A/G genotyping was done by MALDI-TOF MS support from CapitalBio Corporation (Beijing, China), using the MassARRAY system (Sequenom, San Diego, CA, USA) as previously described [ ].

Article Title: Type 2 diabetes is causally associated with depression: a Mendelian randomization analysis.
Article Snippet: Type 2 diabetes (T2D) has been associated with a high prevalence of depression.. We aimed to determine the causal relation by performing a Mendelian randomization (MR) study using 34 T2D risk genetic variants validated in East Asians as the instrumental variable (IV).. An MR analysis was performed involving 11 506 participants from a large longitudinal study.

Software:

Article Title: A Variant in COX-2 Gene Is Associated with Left Main Coronary Artery Disease and Clinical Outcomes of Coronary Artery Bypass Grafting
Article Snippet: Genotyping of the single nucleotide polymorphisms (SNPs, COX-2 rs5275, rs5277, and rs689466) was performed by MALDI-TOF MS support from CapitalBio Corporation (Beijing, China) [ – ].

Article Title: A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
Article Snippet: SNPs were genotyped in Capitalbio Technology Corporation (Beijing, China) by using MALDI-TOF mass spectrophotometry to detect allele-specific primer extension products with the MassARRAY platform (Sequenom, Inc.).

Article Title: Comparative Analysis of Salinity-Induced Proteomic Changes in Cotton (Gossypium hirsutum L.)
Article Snippet: MALDI-TOF-MS ananlysis can deliver high resolution and accurate mass determination of biomolecules including protein digests, which is completed by biotech company (CapitalBio Corporation in China).

Article Title: Absence of association between major vault protein (MVP) gene polymorphisms and drug resistance in Chinese Han patients with partial epilepsy.
Article Snippet: Journal of the Neurological Sciences xxx (2015) xxx–xxx JNS-14106; No of Pages 5 Contents lists available at ScienceDirect Journal of the Neurological Sciences j ourna l homepage: www.e lsev ie r .com/ locate / jns Absence of association between major vault protein (MVP) gene polymorphisms and drug resistance in Chinese Han patients with partial epilepsy Luo Zhou a, Mengqi Zhang a, Hongyu Long a, Lili Long a, Yuanyuan Xie a, Zhaoqian Liu b, Jin Kang a, Qihua Chen a, Li Feng a,⁎, Bo Xiao a,⁎ a Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R.. China b Institute of Clinical Pharmacology, Central South University, Changsha, Hunan 410008, P.R.. China ⁎ Corresponding authors.

Article Title: Interleukin-6 Receptor rs7529229 T/C Polymorphism Is Associated with Left Main Coronary Artery Disease Phenotype in a Chinese Population
Article Snippet: IL-1A rs1800587 C/T, IL-1B rs16944 G/A, IL-6 rs1800796 C/G, IL-10 rs1800872 A/C and IL-10 rs1800896 A/G genotyping was done by MALDI-TOF MS support from CapitalBio Corporation (Beijing, China), using the MassARRAY system (Sequenom, San Diego, CA, USA) as previously described [ ].

Article Title: Type 2 diabetes is causally associated with depression: a Mendelian randomization analysis.
Article Snippet: Type 2 diabetes (T2D) has been associated with a high prevalence of depression.. We aimed to determine the causal relation by performing a Mendelian randomization (MR) study using 34 T2D risk genetic variants validated in East Asians as the instrumental variable (IV).. An MR analysis was performed involving 11 506 participants from a large longitudinal study.



Similar Products

90
Sequenom massarray sequenom detection
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Massarray Sequenom Detection, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc09085879-184-7-8
Average 90 stars, based on 1 article reviews
massarray sequenom detection - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom snps detected by sequenom massarray rs1000 platform
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Snps Detected By Sequenom Massarray Rs1000 Platform, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/massarray+rs1000/pm33127268-102-12-16
Average 90 stars, based on 1 article reviews
snps detected by sequenom massarray rs1000 platform - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom mass spectrometry-based detection (sequenom massarray platform)
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Mass Spectrometry Based Detection (Sequenom Massarray Platform), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc06107190-119-25-28
Average 90 stars, based on 1 article reviews
mass spectrometry-based detection (sequenom massarray platform) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom detection limitation of sequenom massarray
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Detection Limitation Of Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc05863829-107-32-31
Average 90 stars, based on 1 article reviews
detection limitation of sequenom massarray - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom mass spectrometric detection (sequenom massarray)
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Mass Spectrometric Detection (Sequenom Massarray), supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pm26003169-313-9-12
Average 90 stars, based on 1 article reviews
mass spectrometric detection (sequenom massarray) - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom mass spectrometric detection sequenom massarray
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Mass Spectrometric Detection Sequenom Massarray, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/sequenom+massarray/pmc04258414-60-7-10
Average 90 stars, based on 1 article reviews
mass spectrometric detection sequenom massarray - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Sequenom single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system
A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the <t>MassARRAY</t> methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.
Single Nucleotide Extension Reaction With Allele Detection By Mass Spectrometry Sequenom Massarray System, supplied by Sequenom, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/massarray+sequenom+detection/modified+single+nucleotide+extension+reaction+with+allele+detection+by+mass+spectrometry+sequenom+massarray+system/pmc06869631-79-12-14
Average 90 stars, based on 1 article reviews
single-nucleotide extension reaction with allele detection by mass spectrometry sequenom massarray system - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Journal: Cell Death & Disease

Article Title: DNA hypermethylation modification promotes the development of hepatocellular carcinoma by depressing the tumor suppressor gene ZNF334

doi: 10.1038/s41419-022-04895-6

Figure Lengend Snippet: A A negative correlation between ZNF334 methylation level and its mRNA expression (Pearson r = −0.53, R 2 = 0.28) B mRNA expression of ZNF334 in cancer and adjacent tissues of 213 liver cancer patients. C Western-blot diagram of ZNF334 expression in cancer and adjacent tissues of 12 liver cancer patients. D Methylation mass spectrum primers of ZNF334 promoter region and mass spectrometry detection product sequence (green indicates the EPIC chip probe cg07139762 site, which is in the ZNF334 promoter region; yellow indicates the MassARRAY methylation mass spectrometry detection sites, a total of 29). E Heat map of methylation level of ZNF334 promoter region in cancer and adjacent tissues of 25 patients with liver cancer. F The ratio of methylation degree of ZNF334 promoter in cancer and adjacent tissues (T/P) of 25 patients with liver cancer. G The average methylation degree of ZNF334 promoter in cancer and adjacent tissues of 25 patients with liver cancer. **** p < 0.0001.

Article Snippet: And meanwhile, in clinical samples, we used MassArray Sequenom detection to further verify the DNA methylation changes of ZNF334 promoter in cancerous tissues and adjacent tissues.

Techniques: Methylation, Expressing, Western Blot, Mass Spectrometry, Sequencing